EPR Properties vs Novavax Inc — how do they compare? EPR Properties trades at $61.62 (market cap $4.60B), while Novavax Inc trades at $8.25 (market cap $1.39B). The key difference: EPR Properties is far larger — about 3.3× Novavax Inc's market cap, and EPR Properties pays a 6.19% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| EPR | NVAX | |
|---|---|---|
Market Cap | $4.60B | $1.39B |
Sector | Real Estate | Health |
52-Week High | $60.81 | $11.19 |
52-Week Low | $48.71 | $6.22 |
Enterprise Value | $7.66B | $890.94M |
Dividend Yield | 6.19% | — |
Signals from Pluang's Aura AI — not financial advice
EPR Properties (EPR) trades at $61.80, up 3.8% over 24 hours, with a bullish technical signal from moving averages and a consensus analyst price target of $63.25. The REIT maintains strong profitability with a 39.93% net income margin and 10.68% ROE, supported by recent earnings beats and a strategic shift toward experiential assets like the $315 million Six Flags acquisition. Monthly dividends of $0.31 provide a steady income stream, with Q2 2026 earnings results due July 29, 2026.
Outlook remains positive due to high occupancy, dividend yield, and portfolio diversification, but risks include reliance on consumer spending and potential interest rate impacts. Analyst sentiment is mixed with a hold-heavy consensus, suggesting cautious optimism for income-focused investors amid stable fundamentals.
Novavax (NVAX) trades at $8.42, down 5.5% on the day, reflecting a bearish technical trend. Despite a low P/E of 3.14 and recent earnings beats, the company reported a net loss margin of -14.73% for 2026 and negative cash flows. Analyst consensus is a 'Buy' with a $14.00 price target, but technical indicators signal selling pressure. Recent news highlights stock volatility and shareholder dissent at the AGM.
The outlook is mixed: strong valuation ratios and earnings beats offer upside potential, but persistent negative cash flow, high debt, and competitive pressures pose significant risks. Investor sentiment is cautious amid bearish technical signals and uncertain revenue sustainability beyond 2025.
Trailing returns across standard periods
EPR Properties is a REIT specializing in experiential real estate, including movie theaters and leisure destinations like ski resorts and water parks across the US and Canada.
Read more on EPR →Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →